129 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
51 | 26572910 | Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods. | 2015 Dec | 1 |
52 | 27057293 | Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. | 2015 Oct-Dec | 1 |
53 | 28834677 | Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone. | 2015 Sep | 2 |
54 | 24297687 | Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). | 2014 Jan | 1 |
55 | 24486397 | Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers. | 2014 Mar 5 | 1 |
56 | 24493871 | Aldosterone synthase inhibitors in cardiovascular and renal diseases. | 2014 Feb | 1 |
57 | 24713303 | Mineralocorticoid receptor function in bone metabolism and its role in glucocorticoid-induced osteopenia. | 2014 May 9 | 1 |
58 | 25016400 | Comparison of agents that affect aldosterone action. | 2014 May | 1 |
59 | 25016401 | Aldosterone blockade in chronic kidney disease. | 2014 May | 1 |
60 | 23006216 | Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males. | 2013 Mar | 1 |
61 | 23171954 | Mineralocorticoid receptor antagonists: their use and differentiation in Japan. | 2013 Mar | 1 |
62 | 23333184 | Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications. | 2013 Apr | 1 |
63 | 23349535 | Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? | 2013 Feb | 1 |
64 | 23456826 | Rho kinase pathway is likely responsible for the profibrotic actions of aldosterone in renal epithelial cells via inducing epithelial-mesenchymal transition and extracellular matrix excretion. | 2013 Jul | 2 |
65 | 23582279 | Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. | 2013 Dec | 1 |
66 | 23661677 | Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt. | 2013 Jul | 1 |
67 | 23719402 | Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. | 2013 Nov-Dec | 1 |
68 | 23740451 | Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. | 2013 May | 1 |
69 | 23838006 | Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its α-kinase domain. | 2013 Nov | 1 |
70 | 23881669 | Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms. | 2013 Sep | 1 |
71 | 23888997 | Mineralocorticoid receptor and cardiac arrhythmia. | 2013 Dec | 4 |
72 | 24120080 | Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. | 2013 Oct 25 | 1 |
73 | 24133375 | Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. | 2013 Oct 4 | 1 |
74 | 24231917 | Management of patients with resistant hypertension: current treatment options. | 2013 Oct 22 | 1 |
75 | 22205191 | Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. | 2012 Feb | 2 |
76 | 22214629 | Eplerenone improved hypokalemia in a patient with Gitelman's syndrome. | 2012 | 1 |
77 | 22411952 | Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. | 2012 May 1 | 1 |
78 | 22608985 | Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. | 2012 Jul 1 | 1 |
79 | 22684104 | Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. | 2012 Jul | 1 |
80 | 22717248 | Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. | 2012 Nov-Dec | 1 |
81 | 22778046 | Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications. | 2012 Oct | 1 |
82 | 22791416 | Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. | 2012 Aug | 2 |
83 | 23023156 | Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro. | 2012 Nov | 2 |
84 | 21144811 | [Aldosterone and kidney diseases: an emergent paradigm with important clinical implications]. | 2011 Jun | 1 |
85 | 21186336 | Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. | 2011 | 1 |
86 | 21190955 | Aldosterone/Mineralocorticoid receptor stimulation induces cellular senescence in the kidney. | 2011 Feb | 2 |
87 | 21207206 | Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. | 2011 Mar | 1 |
88 | 21731887 | Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. | 2011 | 1 |
89 | 21896143 | Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. | 2011 Sep | 1 |
90 | 22032706 | Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. | 2011 Nov 1 | 2 |
91 | 20535129 | Aldosterone and mineralocorticoid receptor antagonists modulate elastin and collagen deposition in human skin. | 2010 Oct | 2 |
92 | 20625290 | Aldosterone blockade in chronic kidney disease: can it improve outcome? | 2010 Sep | 1 |
93 | 18040710 | Mineralocorticoid receptor is essential for corticosteroid-induced up-regulation of L-type calcium currents in cultured neonatal cardiomyocytes. | 2008 May | 1 |
94 | 18084345 | Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. | 2008 Jan | 2 |
95 | 18555797 | Aldosterone modifies hemostasis via upregulation of the protein-C receptor in human vascular endothelium. | 2008 Aug 22 | 1 |
96 | 18585409 | Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. | 2008 Nov 29 | 2 |
97 | 18729003 | Mineralocorticoid receptor antagonists and endothelial function. | 2008 Sep | 2 |
98 | 17596522 | Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. | 2007 Sep | 2 |
99 | 17645055 | [Aldosterone receptor antagonists]. | 2007 May 30 | 1 |
100 | 17827916 | [Molecular mechanism of cardiovascular damage induced by aldosterone]. | 2007 Sep | 1 |